These similarities and the evidence from animal studies demonstrating that intranasal insulin improved cognition in APP/PS1 mice (Mao et al., 2016) and also in 3xTg AD mice, aged animals and Aβ-treated animals (Ohyagi et al., 2019), triggered an interest in assessing insulin as a potential therapy in AD. Here, APP is linked to Alzheimer disease.